相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy
Yihui Song et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
A small molecule inhibitor targeting SHP2 mutations for the lung carcinoma
Qing Nian et al.
CHINESE CHEMICAL LETTERS (2021)
Discovery of 6-[(3S,4S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor
Barbara Czako et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Sensitive Measurement of Drug-Target Engagement by a Cellular Thermal Shift Assay with Multiplex Proximity Extension Readout
Rasel A. Al-Amin et al.
ANALYTICAL CHEMISTRY (2021)
A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2)
Zachary Hartman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects
Zachary Hartman et al.
ACS OMEGA (2020)
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement
Yelena Mostinski et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis
Hua Zhao et al.
ONCOGENE (2019)
Transition-metal-based (Co2+, Ni2+ and Cd2+) coordination polymers constructed by a polytopic ligand integrating both flexible aliphatic and rigid aromatic carboxylate groups: Aqueous detection of nitroaromatics
Xu-Feng Yang et al.
POLYHEDRON (2017)
Structural and Functional Consequences of Three Cancer-Associated Mutations of the Oncogenic Phosphatase SHP2
Jonathan R. LaRochelle et al.
BIOCHEMISTRY (2016)
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Jorge Garcia Fortanet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases
Ying-Nan P. Chen et al.
NATURE (2016)
SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal- like and triple-negative breast cancer
Fatimah Matalkah et al.
BREAST CANCER RESEARCH (2016)
Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment
Hua Zhao et al.
BMC CANCER (2015)
Noonan and LEOPARD syndrome Shp2 variants induce heart displacement defects in zebrafish
Monica Bonetti et al.
DEVELOPMENT (2014)
Therapeutic Potential of Targeting the Oncogenic SHP2 Phosphatase
Li-Fan Zeng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)
Wei Qiu et al.
BMC STRUCTURAL BIOLOGY (2014)
Determinants of the tumor suppressor INPP4B protein and lipid phosphatase activities
Sandra M. Lopez et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2013)
The anti-inflammatory compound BAY-11-7082 is a potent inhibitor of protein tyrosine phosphatases
Navasona Krishnan et al.
FEBS JOURNAL (2013)
Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations
Zhi-Hong Yu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
The Tyrosine Phosphatase SHP2 Regulates Focal Adhesion Kinase to Promote EGF-Induced Lamellipodia Persistence and Cell Migration
Zachary R. Hartman et al.
MOLECULAR CANCER RESEARCH (2013)
Targeting Protein Tyrosine Phosphatase SHP2 for the Treatment of PTPN11-Associated Malignancies
Bing Yu et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase
K. Miura et al.
ONCOGENE (2013)
Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop
Nicola Aceto et al.
NATURE MEDICINE (2012)
Primary trastuzumab resistance: new tricks for an old drug
Jason A. Wilken et al.
TOWARD PERSONALIZED MEDICINE FOR CANCER (2010)
Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112
Liwei Chen et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Guanglei Zhuang et al.
CANCER RESEARCH (2010)
Salicylic Acid Based Small Molecule Inhibitor for the Oncogenic Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2)
Xian Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Hepatocyte growth factor (HGF) signals through SHP2 to regulate primary mouse myoblast proliferation
Ju Li et al.
EXPERIMENTAL CELL RESEARCH (2009)
Molecular Mechanism for SHP2 in Promoting HER2-induced Signaling and Transformation
Xiangdong Zhou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells
X-D Zhou et al.
CELL DEATH AND DIFFERENTIATION (2008)
SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis
X. Zhou et al.
HISTOPATHOLOGY (2008)
Specific inhibitors of the protein tyrosine phosphatase Shp2 identified by high-throughput docking
Klaus Hellmuth et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Modulation of α-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3
J. Burks et al.
ONCOGENE (2006)
Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
TA Halgren et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Shp2 regulates Src family kinase activity and Ras/Erk activation by controlling Csk recruitment
SQ Zhang et al.
MOLECULAR CELL (2004)
Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling
YM Agazie et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3
YM Agazie et al.
ONCOGENE (2003)
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
G Dontu et al.
GENES & DEVELOPMENT (2003)
Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene
Y Agazie et al.
ONCOGENE (2002)
分享论文
